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Available online 24 October 2013Abstract In vitro stimulation of HSCs with growth factors generally leads to their depletion. Understanding the molecular
mechanisms underlying expansion of HSCs in vivo following myeloablation could lead to successful expansion of HSCs ex vivo for
therapeutic purposes. Current findings show that mTORC1 is activated in HSPCs following 5-fluorouracil treatment and that
mTORC1 activation is dependent onmitochondrial ETC capacity of HSPCs. Moreover, expression of PGC-1 familymembers, proteins
that regulate mitochondrial biogenesis, in HSPCs following 5-fluorouracil treatment changes; also, these proteins play a stage
specific role in hematopoietic recovery. While PRC regulates HSCs' expansion during early recovery phase, PGC-1α regulates
progenitor cell proliferation and recovery of hematopoiesis during later phase. During early recovery phase, PRC expression,
mitochondrial activity and mTORC1 activation are relatively higher in PGC-1α−/− HSCs compared to WT HSCs, and PGC-1α−/− HSCs
show greater expansion. Administration of rapamycin, but not NAC, during early recovery phase improves WT HSC numbers but
decreases PGC-1α−/− HSC numbers. The current findings demonstrate that mTOR activation can increase HSC numbers provided
that the energy demand created by mTOR activation is successfully met. Thus, critical tuning between mTORC1 activation and
mitochondrial ETC capacity is crucial for HSC maintenance/expansion in response to mitogenic stimulation.
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Open access undeIntroduction
Expansion of hematopoietic stem cells (HSCs) in vitro using
growth factors has been thwarted by findings that there is loss
of HSCs during in vitro expansion. In steady-state hematopoi-
esis, a majority of HSCs remain quiescent; however, in response
to 5-fluorouracil (5-FU) treatment, majority of HSCs undergo
rapid proliferation and lead to hematopoietic recovery
(Harrison and Lerner, 1991). Therefore, a better understanding
of molecular pathways that regulate HSC expansion and
recovery of hematopoiesis following 5-FU treatment mayr the CC BY-NC-ND license.
179Interplay between PGC-1 co-activators and mTORC1 regulates hematopoietic recoveryallow us to develop protocols that will eventually lead to
successful ex vivo expansion of HSCs.
Mammalian target of rapamycin (mTOR) kinase is the
catalytic subunit of two complexes, mammalian target of
rapamycin complex (mTORC) 1 and 2; mTORC1 and 2 have been
respectively characterized as the rapamycin-sensitive and
rapamycin-insensitive complexes (Laplante and Sabatini,
2009). Growth factors stimulate the mammalian target of
rapamycin complex1 (mTORC1) pathway that controls cell
growth and division (Fingar and Blenis, 2004). Activation of
mTOR is regulated by adenosine triphosphate (ATP) levels
in the cell (Dennis et al., 2001). Oxidative phosphorylation
(OXPHOS), an oxygen dependent process that occurs in
the mitochondria, is the major source of cellular ATP. Taken
together, these findings raise the possibility that the interaction
between the molecular pathways, mTOR activation
and mitochondrial biogenesis, plays a deterministic role
in ability of hematopoietic stem and progenitor cells (HSPCs)
to successfully expand following 5-FU treatment. Mitochondria
have their own DNA that encodes for 13 essential proteins of
inner membrane respiratory apparatus but nuclear genes
encode for a majority of respiratory proteins and all other
gene products necessary for a variety of mitochondrial
functions. The nucleo-mitochondrial interactions depend on
regulation of transcription factors and peroxisome
proliferator-activated receptor gamma co-activator (PGC-1)
family of transcriptional co-activators that includes PGC-1α,
PGC-1β and PGC-1 related coactivators (PRC) (Scarpulla, 2008).
Although various PGC-1 family members can regulate mito-
chondrial biogenesis (Scarpulla, 2002; Uldry et al., 2006),
PGC-1α is considered the master regulator of mitochondrial
biogenesis (Puigserver and Spiegelman, 2003). PGC-1α is
expressed in BM hematopoietic stem progenitor cells (HSPCs)
(Basu et al., 2013).
While glycolysis is important for the maintenance of HSCs
(Simsek et al., 2010; Takubo et al., 2010), the role of
mitochondrial metabolism in hematopoiesis (Nakada et al.,
2010; Gurumurthy et al., 2010), particularly in response to
stress (Mortensen et al., 2011), is increasingly being
realized. Indeed, recovery of peripheral blood cells (PBCs)
following 5-FU treatment is significantly impaired in PGC-1α
knockout (PGC-1α−/−) mice compared to wild type (WT)
mice; however, steady-state hematopoiesis is not overtly
affected in PGC-1α−/− mice (Basu et al., 2013). Moreover,
the impairment of PBC recovery is more profound in older
PGC-1α−/− mice (SB unpublished observation) consistent
with age related degeneration of mitochondrial function (Pieri
et al., 1993). These findings suggest a role of mitochondria in
the recovery of hematopoiesis following 5-FU treatment.
To get an insight into mechanisms regulating HSC prolifer-
ation in vivo, recovery of hematopoiesis following 5-FU
treatment in WT and PGC-1α−/− mice was investigated in this
study. The current study demonstrates that mitochondrial
biogenesis is critical for HSPCs to optimally respond to
mTORC1 activation and proliferate in response to mitogenic
signals following 5-FU challenge. Moreover, the level of
mTORC1 activation is regulated by the mitochondrial
biogenesis potential of HSPCs. Interestingly, different
members of the PGC-1 family play stage-specific roles in
hematopoietic recovery following 5-FU treatment: while
PRC is required for hematopoietic stem cell (HSC) prolifer-
ation during early recovery phase, PGC-1α is important forrapid proliferation of progenitors during late phase of
hematopoietic recovery following 5-FU treatment.
Material and methods
Animal studies
All animal studies were evaluated and approved by the
Institutional Animal Care and Use committee. PGC-1α knockout
(PGC-1α−/−) mice were a kind gift from Prof. B. Spiegelman
(DFCI, Boston, MA) and used after 9 backcrosses to C57/Bl6
mice. PGC-1α+/+ littermatemicewere used as a control and are
designated as wild type (WT) in this study. C57/Bl6 mice were
purchased from Jackson Laboratories; C57/Bl6:BoyJ F1 and
Boy/J mice were from the In Vivo Core Therapeutic Facility of
the Indiana University School of Medicine.
5-FU and rapamycin treatments
Mice were treated with 150 mg/kg wt of 5-FU intraperitoneally
(i.p.) on day 0 and the changes in PBC counts and bone marrow
(BM) cellularity was followed thereafter. Rapamycin
(Sigma-Aldrich) was made in absolute ethanol at 10 mg/ml
and further diluted in 5% Tween-80 (Sigma-Aldrich) and 5%
PEG-400 (Hampton Research) (Chen et al., 2008). Rapamycin
was delivered i.p. so that the measured dose of rapamycin
(adjusted to mouse body weight) could be administered. Mice
received 4 mg/kg rapamycin on days 1 and 3 or on day 8
post-5-FU treatment.
Phenotypic and functional analysis of BM cells
BM cells were obtained from the long bones (tibias and
femurs) of mice. Lineage positive cells were identified based
on staining pattern with fluorescent dye conjugated anti-
bodies against B220, CD3, Gr-1, Mac-1, CD71 and Ter119 (BD
Biosciences). The above set of antibodies, except CD71, was
used to gate out the lineage positive cells for analysis of
HSC/progenitor populations. For analysis of 5-FU treated BM
on day 4 Mac-1 was not included in the lineage cocktail
antibody for gating out lineage negative cells (Randall and
Weissman, 1997). c-Kit+Sca-1+IL-7R−Lin− cells are designat-
ed as KSL and c-kit+IL-7R−Lin− cells are designated as KL/MP.
HSCs are defined as KSL IL-7R−CD34−, and MPPs defined as
KSL IL-7R−CD34+. Since the expression of CD34 on HSCs alters
following 5-FU treatment (Sato et al., 1999), I used SLAM
marker in conjunction with KSL (Yilmaz et al., 2006) to
enumerate changes in primitive and progenitor cell popula-
tions in the BM for up to 7 days following 5-FU treatment.
The combination of SLAM markers used to identify progen-
itors differs between Yilmaz et al. (2006) and Wilson et al.
(2008) and in this study the identification of the progenitors
has been done as described by Yilmaz et al. (2006).
Fluorochrome conjugated antibodies were purchased from
eBioscience, Biolegend and BD Bioscience. Flow cytometry
analysis was performed on an LSR II (BD Biosciences), and
cells were sorted using FACSAria (BD Biosciences). Cell cycle
status was determined by fixing and permeabilizing cells
with BD Per/Fix buffer reagents (BD Pharmingen) and
staining the cells with 2 μg/ml HOECHST 33342 (Invitrogen)
180 S. Basufor 10 min followed by washing the cells and then staining
with 4 μg/ml PyroninY. Mice were injected i.p. with BrdU
(Sigma) at a dose of 0.1 mg/g body mass. BrdU uptake by BM
cells was analyzed by staining the cells with anti-BrdU-APC
staining kit (BD Pharmingen).ROS, mitochondrial activity, ATP, NADH,
and mTORC1 activation
Reactive oxygen species (ROS) and mitochondrial activity in
various BM sub-populations were measured using the
fluorescent dyes 2′,7′-dichlorofluorescein diacetate DCFDA
(Invitrogen) and MitoTracker Deep Red (MDR) (Invitrogen),
respectively as previously described (Basu et al., 2013).
Mitochondrial transmembrane potential (Δψm) was assessed in
live cells by staining with JC-1 dye as described earlier (Basu et
al., 2013; Cossarizza and Salvioli, 2001). ATP content was
measured using Cell-Titer-Glo luminescent cell viability kit
(Promega) as described previously (Basu et al., 2013). Endog-
enous NADH fluorescence was measured using flow
cytometrically using a UV laser (LSR II, BD Biosciences)
(Chance and Thorell, 1959). For measuring mTORC1 activation,
BM cells were fixed using 1.5% paraformaldehyde, perme-
abilized using cold acetone as described previously (Kalaitzidis
and Neel, 2008) and then stained with Alexa-488 conjugated
phosphorylated S6 ribosomal protein (pS6) or control antibody
(Cell Signaling). The samples were analyzed using flow
cytometry using FlowJo software. As a measure of mTORC1
activation, the level of phosphorylated p70S6kinase (Thr389)
(pp70S6K) was measured using western blot, in addition to pS6.0
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Figure 1 Kinetics of changes in peripheral blood cell count and
changes in peripheral blood cell count following 5-FU challenge in (Ai
(n = 4–5 mice per genotype, *p b 0.02 compared to WT mice). (Bi)
compared to basal level and (Bii) change in PGC-1α−/− BM cellularit
per time point; *p b 0.05 compared to WT mice).Western blot
Lineage negative cells were sorted based on staining pattern of
BM cells with fluorescent dye conjugated antibodies against
B220, CD3, Gr-1, Mac-1, and Ter119 (Mac-1 antibody was not
included in the antibody cocktail for sorting of day 4 post-5-FU
BM cells). Cells were lysed and were electrophoresed on 4–
12% Tris-glycine gel (Invitrogen) and then blotted onto a
polyvinyl difluoride (PVDF) membrane (Basu and
Broxmeyer, 2005). The membrane was probed with
different antibodies: pp53 (ser15), p53, pACC (ser79),
pAMPK-α (Thr172), AMPKα, pp90RSK (Thr359/Ser363),
pp70S6K (Thr389) (Cell Signaling) and β-actin (Sigma).
Between probing with each antibody the blot was stripped
using stripping buffer and thereafter washed 3 times with
wash buffer.
Gene expression by qRT-PCR
mRNAwas isolated and cDNA prepared usingMACS cDNAmodule
(Miltenyi Biotec) from freshly sorted cells. Expression of genes
was studied using real-time polymerase chain reaction (PCR;
Stratagene, Mx3000P) based on SYBR Green (Invitrogen)
monitoring of PCR product accumulation. PCR primer pairs
were purchased from SABioscience.
Bone marrow transplantation
The recipient mice were fed with doxyrubicin for a week
before irradiation (950 rad) and continued on the0
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181Interplay between PGC-1 co-activators and mTORC1 regulates hematopoietic recoverydoxyrubicin supplemented feed for the next 2 months to
prevent spontaneous infection. Competitive repopulation
assays were performed as previously described. Briefly,
either 2 × 105 (1:1 group) or 0.5 × 105 (0.25:1 group) BM
cells from either PGC-1α−/− mice or C57/Bl6 mice (CD45.2)
were mixed with 2 × 105 BM cells from BoyJ (CD45.1) mice
and injected into irradiated recipient C57/Bl6:BoyJ
F1double-positive recipients (CD45.1:CD45.2). PB was ob-
tained from the tail veins of recipients at indicated times to
monitor chimerism. RBCs were lysed by RBC lysis buffer
(ammonium chloride/potassium bicarbonate buffer) before
staining. For secondary transplant, BM cells from each of the
primary recipient were injected into three irradiated
(950 rad) secondary recipients (2 × 106 cells/secondary
recipient mouse). Chimerism in PB was evaluated 2 months
after transplantation.
Statistical analysis
Data is presented as mean ± SD unless indicated otherwise.
Significance of differences was analyzed using Student's 2-tailed
t-test.
Results
Loss of PGC-1α has a differential effect on early and
late phase of hematopoietic recovery following
5-FU treatment
5-FU treatment kills proliferating progenitors but spares the
HSCs (Lerner and Harrison, 1990). Proliferation of HSCs and
progenitors in the BM precedes recovery of PBC count following
5-FU treatment (Harrison and Lerner, 1991). Indeed, 5-FU
treatment led to reduction in BM cellularity in both WT and
PGC-1α−/− mice (Fig. 1A). BM cellularity was lower in
PGC-1α−/− than in WT mice on days 9 and 10 (Fig. 1B),
surprisingly, on day 4, BM cellularity was significantly higher in
PGC-1α−/− than in WT mice (Figs. 1A–B). Recovery of BM
hematopoiesis following 5-FU treatment occurs broadly in two
phases. In the first phase (from days 2 to 5), HSCs are
stimulated to proliferate rapidly to replenish the progenitor
cell pool; however, very little progenitor expansion occurs
during this period, and both BM cellularity and PBC counts
reach nadir (Harrison and Lerner, 1991; Randall and Weissman,
1997; Jansen et al., 1991). In the second phase, proliferation of
HSCs returns to near normal level, but MPs proliferate rapidly
followed by an overshoot of BM and PBC counts, which
eventually return to normal level. Therefore, to understand
why recovery of PBC counts in PGC-1α−/−mice is compromised,
I examined these two phases of recovery, which will hereafter
be referred to as early and late phases of hematopoietic
recovery in PGC-1α−/− and WT mice following 5-FU treatment.
Early phase of hematopoietic recovery—Increased HSC
and MP pools in BM of PGC-1α−/− mice following
5-FU treatment
On day 4 post-5-FU both BM cellularity and PBC count were
higher in PGC-1α−/− than in WT mice (Fig. 2Ai–ii). Also,
both the proportions and total numbers of MP and HSC
were higher in PGC-1α−/− than in WT mice on day 4
(Fig. 2Bi–iii). The difference in progenitor and HSCnumbers in PGC-1α−/− from those in WT mice on day 4
was not due to a difference in susceptibility of WT and
PGC-1α−/− BM cells to the killing effect of 5-FU as the
reduction in PBC count, total BM cellularity, composition
of early and mature BM cells, cell cycle status, and
apoptotic BM cells were comparable between PGC-1α−/−
and WT mice on day 1 post-5-FU treatment (Fig. S1Ai–v, B
& Ci–ii). Therefore, the larger HSPC pool on day 4 in
PGC-1α−/− mice was likely due to a greater proliferation of
PGC-1α−/− HSPCs. To investigate this possibility,
bromodeoxyuridine (BrdU) was injected into the mice on
day 3 post-5-FU treatment. Examination of BM cells 24 h
post-BrdU injection revealed that a significantly greater
proportion of MPs (identified as IL-7R−KL) and HSC
enriched fraction (IL-7R−KSL) of BM cells were proliferat-
ing in PGC-1α−/− compared to WT mice. These cells were
also cycling faster in PGC-1α−/− mice since a greater
proportion of these cells in the G0/G1 phase were BrdU
positive (Fig. 2Ci–iii) in these mice. Moreover, significant-
ly lower proportions of IL-7R−KSL cells and MPs underwent
apoptosis as demonstrated by the comparatively lower
proportion of cells in the subG0 fraction in PGC-1α−/−
compared to WT mice (Fig. 2Ci–iii). Thus, enhanced
proliferative potential coupled with lower apoptosis of
HSCs and MPs in PGC-1α−/− mice compared to WT mice
during the early recovery phase results in increased HSC
and MP pools in these mice.
HSCs are spared by a single dose of 5-FU; however, a second
dose of 5-FU, administered 4 days after the primary dose, kills
a significant number of HSCs (Harrison and Lerner, 1991).
Indeed, total numbers of both MPs and HSCs (Fig. 2Di–iv) were
significantly reduced in both WT and PGC-1α−/− mice
following (next day) two doses of 5-FU, administered on days
0 and 4. Interestingly, total numbers of HSCs and MPs were
higher in PGC-1α−/− compared to WT mice after 2 doses of
5-FU (Fig. 2Diii–iv). 5-FU kills actively cycling cells and
significantly greater proportions of MPs and HSCs were found
to be actively cycling following a single dose of 5-FU in
PGC-1α−/− mice. This finding suggested that PGC-1α−/− HSCs
have enhanced proliferative potential following 5-FU treat-
ment, enabling them to regenerate more HSCs. Indeed, a
greater proportion of PGC-1α−/− HSCs compared toWTwere in
cell cycle following 2 doses of 5-FU treatment (Fig. S2).
Despite an increase in phenotypically defined HSC and MP
pools in PGC-1α−/− mice during early recovery phase, attenu-
ated recovery of blood cells in PGC-1α−/− compared toWTmice
following 5-FU treatment raised questions about the functional
status of phenotypically identified PGC-1α−/− HSC population.
To address this issue, BM cells of 5-FU treated WT and
PGC-1α−/− mice were used in competitive repopulation assay
using BM cells from BoyJ mice as the competitor cells.
PGC-1α−/− BM cells harvested 6 days post-5-FU treatment had
greater competitive re-populating activity than similarly treat-
edWT BM cells (39.6 ± 16% vs 2.5 ± 2.2% PGC-1α−/− vsWT cells,
respectively, in PB of recipient mice at 4 months post-trans-
plantation; at 0.25:1 donor: competitor ratio, 5 × 104 donor
cells in a graft). This difference in repopulating activity is
not due to a difference in homing ability of WT and
PGC-1α−/− BM cells as indicated by a similar proportion of
WT and PGC-1α−/− BM cells in recipient mice BM on day 8
(Figs. S3A–C), although donor cell contribution in recipi-
ent mice was different 14 days post-transplantation.
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Figure 2 HSC and progenitor cell numbers in the BM during early and late recovery phases of hematopoiesis following 5-FU
challenge. (Ai) PBC and (Aii) total BM cell (2 femurs and 1 tibia) counts on day 4 post-5-FU challenge. (Bi) Representative dot plot
showing changes in HSCs and progenitor cells on day 4. (Bii) Total numbers of HSCs, multipotential progenitors and (Bii) MPs in BM
(2 tibias and 1 femur) on day 4 (n = 3–5; *p b 0.05). (Ci) Mice were treated with 5-FU (150 mg/kg wt) and injected with BrdU
(i.p.) 3 days later. 24 h post-BrdU injection, BM cells were harvested and stained with fluorochrome conjugated antibodies
against specific surface markers and BrdU as detailed in Materials and methods. Representative dot blot showing cell cycle status
of HSC enriched fraction and progenitor cells on day 4. Proportion of (Cii) MPs (IL-7R−KL) and (Ciii) HSC enriched (IL-7R−KSL) BM cells in
undergoing proliferation and apoptosis in WT and PGC-1α−/− mice on day 4 are shown (n = 3; *p b 0.05, compared to WT mice). (Di) BM
cellularity, (Dii) lineage negative, (Diii) MPs, (Div) and HSCs of WT and PGC-1α−/− mice following two doses of 5-FU administered 4 days
apart and those of untreated WT mice are shown (n = 3; *p b 0.05). (E) Comparison of repopulating activity of BM cells of WT and
PGC-1α−/− mice harvested on day 6 following 2 doses of 5-FU treatment, administered 3 days apart (days 0 and 4), and BM cells from
untreated WT mice is shown (n = 5 recipient mice in each group; * p b 0.05 compared to WT mice treated with 2 doses of 5-FU). (Fi–iii)
Total number of lineage negative cells, MPs as well as HSCs cells (in 2 tibias + 1 femur is shown) is shown on day 7 (n = 3; p b 0.05
compared toWTmice). (G) Total MPs and HSC enriched population (IL-7R−KSL) on day 9 post-5-FU challenge are shown. (Hi) BM cells were
stained with a panel of fluorochrome conjugated phenotype defining specific antibodies and then fixed and stained with Hoechst and
anti-Ki-67 antibody. Cell cycle status of MPs and HSC enriched fraction (IL-7R−KSL) on day 7 was determined by FACS analysis. Proportions
of (Hii) MPs and (Hiii) HSC enriched fraction of cells at the various stages of cell cycle on day 7 are shown (n = 3; p b 0.05 compared toWT
mice).
183Interplay between PGC-1 co-activators and mTORC1 regulates hematopoietic recoveryFurthermore, consistent with previous reports, competi-
tive repopulating potential of WT and PGC-1α−/− BM cells
were significantly reduced when 2 doses of 5-FU were
administered 5 days apart (contribution of donor derived
cells in peripheral blood of recipient mice at 0.25:1 donor
competitor cell ratio: 0.25 ± 0.3 (WT) and 2.5 ± 2.8%
(PGC-1α−/−) after doses of 5-FU compared to 2.5 ± 2.2(WT) versus 39.6 ± 16% (PGC-1α−/−) after 1 dose of 5-FU, at
4 months). However, relative repopulating activity of
PGC-1α−/− BM cells was higher than WT BM cells as observed
in response to single dose of 5-FU (Fig. 2E). This finding
confirmed that there is a greater expansion of long
term-repopulating cells in PGC-1α−/− mice compared to
WT mice following 5-FU treatment.
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185Interplay between PGC-1 co-activators and mTORC1 regulates hematopoietic recoveryLate phase of hematopoietic recovery—Proliferation
of MPs is compromised in PGC-1α−/− mice
Impaired recovery of PBCs following 5-FU treatment in
PGC-1α−/− mice, despite higher proliferative potential and a
larger pool of HSCs during early phase, suggested that
proliferative capacity of hematopoietic progenitors during
second phase is impaired in PGC-1α−/− mice. Indeed, the
differences between WT and PGC-1α−/− mice in total BM
cellularity and in HSPC pool observed on day 4 narrowed on day
7 (Figs. 1A–B & 2Fi–iii), and this was followed by a reversal of
the trend in BM cellularity and composition on day 9 (Figs. 1A–B
& 2G). There were fewer HSCs on day 7 in PGC-1α−/− compared
to WT mice and both the total number of BM cells, MPs and
IL-7R−KSL cells were lower in PGC-1α−/− compared to WT mice
(Fig. 2G) on day 9. Moreover, the proliferative potential of the
MPs was impaired in PGC-1α−/− mice (Fig. 2Hi–iii). These
findings demonstrate that the defect in the later recovery
phase underlies the impaired recovery of blood cells in
PGC-1α−/− mice following 5-FU treatment.
Analysis of mTORC1 activation, PGC-1 family
members' expression, and mitochondrial
metabolism following 5-FU treatment
Early phase of hematopoietic recovery
Cytokine-stimulated mTORC1 signaling plays an important
role in cell growth and division (Sengupta et al., 2010). To
gain insight into the molecular mechanism underlying the
differences in proliferative potential of WT and PGC-1α−/−
HSPCs post-5-FU treatment, I therefore, evaluated mTORC1
activation level in WT and PGC-1α−/− HSPCs. Basal mTORC1
activation levels of WT and PGC-1α−/− BM cells, as measured
by pS6 level, were comparable (Fig. S4). However, on day 4,
pS6 level was higher in PGC-1α−/− HSPCs compared to WT
(Fig. 3Ai). Moreover, pp70S6k (Thr389) was also higher in
PGC-1α−/− HSPCs compared to WT; however, no difference
in phosphorylation state of p90RSK was observed (Fig. S5)
thus demonstrating that mTORC1 activity was higher in
PGC-1α−/− HSPCs compared to WT on day 4. Moreover,
PGC-1α−/− HSPCs were larger in size compared to WT HSPCs
(Fig. 3Aii), consistent with higher mTORC1 activation (Fingar
and Blenis, 2004). Activation of mTORC1 leads to biosyn-
thetic processes, increasing demand for energy. Therefore,
it is conceivable that activation of mTORC1 would lead toFigure 3 mTORC1 activation and mitochondrial activity during ear
of (A) phospho-S6 level and (Aii) cell size as measured using flow c
(IL-7R−KSL) of BM cells of WT and PGC-1α−/− mice are shown (n = 3–5
(Bii) mitochondrial activity of various sub-populations of BM cells o
pattern, as a measure of Δψm, of various fractions of BM cells and (C
(IL-7R−KL) and IL-7R−KSL cells of WT and PGC-1α−/− mice on day 4 are
pattern, as a measure of intracellular ROS level and (Dii) quantitativ
PGC-1α−/− mice on day 4 are shown (n = 3, *p b 0.05). (Diii) Repr
PGC-1α−/− sub-population of BM cells on day 4 post-5-FU challenge. (
4 and day 7 post-5-FU challenge (n = 3 mice in each experiment). (E
cells and Tfam expression pre- and post-5-FU treatment in (Ei) WT an
PRC on day 0 and various days post-5-FU treatment in WT and PGC-
experiments and in each experiment 3 mice of each genotype for eacincreased mitochondrial metabolism to meet the increased
demand for ATP. On day 4, mitochondrial masses of
PGC-1α−/− and WT HSPCs were comparable (Fig. 3Bi);
however, a greater proportion of WT MPs (IL-7R−KL) had
higher mitochondrial activity, indicated by MitoTracker
Deep Red (MDR) fluorescence intensity and mitochondrial
transmembrane potential (Δψm) (JC-1aggregate MFI) (Figs. 3Bii
& Ci–ii). Interestingly, the proportion of IL-7R−KSL cells with
actively respiring mitochondria was higher in PGC-1α−/−
compared to WT mice, demonstrated by MDR and JC-1
staining (proportion of cells expressing JC-1aggregate) (Figs.
3Bii & Ci). JC-1 is a protonic dye, meaning its accumulation
inside the mitochondria is dependent on the polarized state
of mitochondria. JC-1aggregate formation causes a shift from
green to red fluorescence emission with increasing concen-
tration of the dye accumulation (i.e., aggregation) in the
mitochondria instead of fluorescence quenching (Smiley et
al., 1991). Therefore, the fluorescence intensity of the JC-1
aggregate is an indication of the mitochondrial membrane
potential in the cell. In addition to high Δψm, intracellular
reactive oxygen species (ROS) and NADH levels were also
higher in WT MPs and HSC enriched fraction of BM cells
(Fig. 3Di–iii), but relative ATP level was lower (Fig. 3Div),
suggesting that WT HSPCs had aberrant mitochondrial
functions on day 4. Although stimulation with growth factors
increases mitochondrial metabolism and Δψm, a dramatic
increase in Δψm makes the cells susceptible to apoptosis
(Banki et al., 1999). Thus, higher Δψm and aberrant
mitochondrial function and lower ATP content of WT HSPCs
(Figs. 3Ci, Di–iv & Fig. S6) explain, at least in part, WT
HSPCs' lower proliferative potential and higher apoptosis on
day 4 post-5-FU treatment.
Comparative differences in Δψm, ATP, intracellular NADH
and ROS levels between WT and PGC-1α−/− HSPCs suggested
that there are differences in respiratory chain capacity
between WT and PGC-1α−/− HSPCs, which could explain the
defects in OXPHOS, and thus energy producing capacity, of
WT HSPCs. Regulation of respiratory chain capacity depends
both on the nuclear and mitochondrial genomes (Scarpulla,
2008; Scarpulla, 2002). Tfam is essential for mtDNA transcrip-
tion; loss of Tfam causes depletion of mtDNA, severe
respiratory chain deficiency, loss of mitochondrial transcripts
and of mtDNA-encoded polypeptides (Larsson et al., 1998).
Although at baseline Tfam expressions are comparable in WT
and PGC-1α−/− HSPC (Fig. S7A), on day 4, Tfam levels were
lower in WT compared to corresponding PGC-1α−/− HSPCsly recovery phase following 5-FU challenge. Representative plot
ytometry on day 4 post-5-FU of MPs and HSC enriched fraction
mice). Representative plot showing (Bi) mitochondrial mass and
n day 4 (n = 3 mice). (Ci) Representative plot of JC-1 staining
ii) the average intensity of JC-1 aggregate fluorescence of MPs
shown (n = 3). (Di) Representative plot showing DCFDA staining
e analysis of ROS level in various fractions of BM cells of WT and
esentative plot indicating intracellular NADH level in WT and
Div) Ratio of ATP in WT and PGC-1α−/− BM subpopulations on day
i) Changes in Tfam expression in PGC-1α−/− compared to WT BM
d (Eii) PGC-1α−/− mice. (Fi–v) Expression of PGC-1α, PGC-1β and
1α−/− mice. *** Not detectable. Data shown is the mean of 2–3
h time point were analyzed (*p b 0.05 compared to basal value).
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Figure 5 mTORC1 activation in vitro by growth factors stimulation and REDD1 level in BM cells following 5-FU challenge. (A) Freshly
isolated BM cells stimulated with thrombopoietin (TPO, 100 ng/ml) or interleukin-3 (IL-3, 50 ng/ml) or cultured in medium alone for
20 min and then they were washed and fixed. Cells were thereafter stained with antibodies against specific surface markers and pS6
or isotype matched antibody. Representative plot of pS6 level in different BM sub-populations is shown (n = 3). (Bi–ii) Fold change in
REDD1 expression in WT and PGC-1α−/− BM sub-populations after 5-FU treatment relative to baseline expression. REDD1 expression in
various sub-populations of PGC-1α−/− BM cells relative to expression in WT BM cells on (Biii) day 4 and (Biv) day 7 post-5-FU treatment
(n = 3, *p b 0.05).
187Interplay between PGC-1 co-activators and mTORC1 regulates hematopoietic recovery(Fig. 3Ei–iii). PGC-1 family of co activators regulates Tfam
expression (Scarpulla, 2008; Kelly and Scarpulla, 2004).
Although HSPCs express all members of PGC-1 family at
steady-state (Basu et al., 2013) PGC-1α and PGC-1β expressions
were not detectable and only PRC expression was detectable in
HSPCs (Fig. 3Fi–v) on day 4 post-5-FU treatment. Importantly,Figure 4 Mitochondrial activity and mTORC1 activation during late
measured by MDR and DCFDA staining patterns, respectively, on (Ai)
cells (n = 3). (Aiii) Proportion of early fractions of BM cells with
mitochondrial activities is shown (n = 3–4 per group, *p b 0.05
Representative dot plots of JC-1 staining pattern as a measure of Δψm
9 are shown. Percentage of IL-7R−KL and of IL-7R−KSL cells with act
day 7 and (Ciii) day 9 and (Cii) Δψm on day 7 based on JC-1aggregate
compared to WT mice). (D) pS6 on day 7 in WT and PGC-1α−/− BM c
PGC-1α−/− IL-7R−KL and IL-7R−KSL cells on day 7 post-5-FU challengexpression of PRC on day 4 was significantly higher in
PGC-1α−/− compared to WT HSPCs (Fig. S7B), particularly in
the CD34+KSL fraction, which contains proliferating HSPCs
during early recovery phase (Sato et al., 1999). PRC can
regulate cellular proliferation by modulating Tfam expression
(Andersson and Scarpulla, 2001), and thus the differences inrecovery phase. Mitochondrial activity and intracellular ROS, as
day 7 and (Aii) day 9 in various fractions of WT and PGC-1α−/− BM
high (MitoTracker+DCFDAhigh) and low (MitoTracker+DCFDAdim)
compared to WT mice and **p b 0.05 compared to day7).
of various sub-populations of BM cells on (Bi) day 7 and (Bii) day
ively respiring mitochondria (expressing JC-1 aggregate) on (Ci)
mean fluorescence intensity (MFI) is shown (n = 3–5, *p b 0.05
ells are shown. (E) Representative plot showing size of WT and
e as measured by flow cytometry is shown (n = 3).
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189Interplay between PGC-1 co-activators and mTORC1 regulates hematopoietic recoveryPRC expression could explain the differences in Tfam expres-
sion between PGC-1α−/− and WT BM sub-populations observed
during early recovery phase.
Late phase of hematopoietic recovery
Unlike day 4, on day 7, detectable levels of PRC as well as
PGC-1α/β were expressed in both WT HSCs and MPs. PGC-1β
expression level on day 7 was comparable to the basal level
while PGC-1α expression in WT MPs was significantly higher
than the basal level (Fig. 3Fi–v).
Coinciding with the higher expression of various PGC-1
family members on day 7 in WT HSPCs, particularly PGC-1α
expression, proportion of MPs and IL-7R−KSL cells undergoing
mitochondrial metabolism was also higher in WT than
PGC-1α−/−mice (Figs. 4Ai, Bi, Ci–ii); this wasmore pronounced
on day 9 (Figs. 4Aii, Bii, Ciii). Moreover, greater proportion of
cells were expressing JC-1agg and intracellular ROS, and ATP
levels were also higher in WT cells suggesting higher mitochon-
drial metabolism in these cells (Figs. 4Ai–iii, 3Ei).
Unlike day 4 when mTORC1 activation was higher in
PGC-1α−/− HSPCs, on day 7 mTORC1 activation was higher in
WTHSPCs (Fig. 4D). Consistent with this finding, themean size
of WT MPs and IL-7R−KSL cells during the later recovery phase
was also relatively bigger than corresponding PGC-1α−/− BM
cells (Fig. 4E).
Differential expression of REDD1 in WT and
PGC-1α−/− mice following 5-FU treatment
Interestingly, mTORC1 activation was higher in WT compared
to PGC-1α−/− BM cells when the cells were stimulated with
growth factors in vitro (Fig. 5Ai–ii), as demonstrated by pS6
level. This finding was inconsistent with mTORC1 levels
observed in HSPCs during early recovery phase but was similar
to that observed during later recovery phase (Fig. 4D). mTORC1
activation is regulated by different pathways, including PI3K/
Akt and REDD1 (Hay and Sonenberg, 2004; Brugarolas et al.,
2004). Activated Akt levels were comparable in WT and
PGC-1α−/− HSPCs following 5-FU treatment (Fig. S5). Thus,
the difference in pS6 levels between WT and PGC-1α−/− HSPCs
on day 4 was not due to differences in Akt activation. Next, I
examined REDD1 expression in these cells at steady-state and
following 5-FU treatment. REDD1 expression is regulated by
ROS (Ellisen et al., 2002), and REDD1 impairs mTORC1
activation (Sofer et al., 2005). Compared to basal levelFigure 6 Effect of rapamycin on HSC and progenitor cell pools follo
in the BM cells of WT and PGC-1α−/− mice, which had been either tre
untreated, are shown. Representative plot shown (n = 3). (B) Effect
(Bi) WT and (Bii) PGC-1α−/−, and IL-7R−KSL cells of (Biii) WT and (B
along with rapamycin treatment as described above (n = 3, *p b 0.0
Total number of MPs and IL-7R−KSL cells and (Cii) HSCs identified usin
shown (n = 3). (Ciii) Competitive repopulating potential of 5-FU t
treatment and that of untreated WT mice is shown. 2 × 105 BM ce
(CD45.1) and injected into lethally irradiated F1 (CD45.1/CD45.2) m
contribution of donor-derived cells in the peripheral blood of recipie
(Di) Total BM cellularity (×106 for 2 femurs) and PBC count (×106/ml
by rapamycin treatment on days 1 and 3 or 5-FU followed by rapamyc
(Dii) HSCs and (Diii) total and sub-sets of MPs are shown (*p b 0.05,(Fig. S7B), expression of REDD1 was higher on day 4 in both
WT and PGC-1α−/− HSPCs (Fig. 5Bi–ii); moreover, relative
expression of REDD1 on day 4 was higher in WT compared to
PGC-1α−/− HSPCs. In contrast, on day 7, REDD1 levels
decreased in both WT and PGC-1α−/− HSPCs, coinciding with
higher expression of the genes regulating mitochondrial
biogenesis and respiratory chain capacity of mitochondria
(Fig. 5Bi–ii). However, relative REDD1 expression on day 7 was
higher in PGC-1α−/− than WT HSPCs (Fig. 5Biii–iv).Effect of rapamycin treatment on HSC and MP
expansion following 5-FU challenge
As shown earlier, mTORC1 is activated in HSPCs following
5-FU treatment (Figs. 3A & 4D). mTORC1 activation leads to
increased demand for ATP, and an increase in ADP/ATP ratio
in cell leads to activation of AMP Kinase (AMPK) (Hardie et
al., 1998; Habib, 2011). Indeed AMPK activity was higher on
day 4 compared to day 1 in lineage negative fraction of both
WT and PGC-1α−/− BM cells (Fig. S8) as indicated by higher
phosphorylation levels AMPK (Thr172) and of ACC(Ser79)
(Munday, 2002). Furthermore, analysis of phospho-p53 blot
showed that, on day 4 while p53 was undergoing degradation
in PGC-1α−/− cells, it was relatively stable in WT cells;
however on day 7, p53 was degraded in both WT and
PGC-1α−/− cells. Expression of PGC-1 family members,
except PRC, decreases in HSPCs following 5-FU treatment;
this finding suggests that the ability of HSPCs to boost
electron transport chain (ETC) capacity during initial
recovery phase is decreased. Therefore, it would be
expected that lowering mTORC1 activation during early
recovery phase would lower energy demand in HSCs and thus
decrease the load on ETC, leading to lower apoptosis and
improved HSC numbers. Indeed, treatment with rapamycin,
an inhibitor of TORC1 pathway, on alternate days (first dose
on day 1 and the second dose administered on day 3)
following 5-FU, did not have any significant effect on
phosphorylation level of p90RSK but decreased phosphory-
lated levels of both p70S6k and S6 ribosomal (Figs. S5 & 6A)
and lowered apoptosis (Fig. 6Bi–iv) in WT and PGC-1α−/− MPs
and IL-7R−KSL cells. Consistent with lowering of mTORC1
activation, cell sizes of WT and PGC-1α−/− MPs and IL-7R−KSL
cells were comparable (Fig. S9A). Also, mitochondrial mass
and activity and ROS levels of WT and PGC-1α−/− MPs and
IL-7R−KSL cells were also comparable (Figs. S9B–D, Ei–iii).wing 5-FU challenge. (A) pS6 levels on day 4 post 5-FU challenge
ated with rapamycin on days 1 and 3 post 5-FU injection or left
of rapamycin treatment on cell cycle status of MPs (IL-7R−KL) of
iv) PGC-1α−/− cells on day 4 following 5-FU treatment alone or
5 compared to no rapamycin treatment of same genotype). (Ci)
g SLAM markers in WT and PGC-1α−/− mice on day 6 post-5-FU is
reated BM cells of WT or PGC-1α−/− mice on day 6 post-5-FU
lls (CD45.2) were mixed with competitor cells from BoyJ mice
ice at 1: donor:competitor cell ratio. Data shows mean (±SD)
nt mice at various time after transplantation (*p b 0.05, n = 5).
) on day 12 of WT mice treated with 5-FU alone or 5-FU followed
in treatment on day 8. Effect of above-mentioned treatments on
n = 3).
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endogenous NADH level is an indicator of mitochondrial
metabolism (Simsek et al., 2010; Chance and Thorell, 1959).
Moreover, antimycin A, an inhibitor of complex III of ETC,
leads to a buildup of NADH in cells undergoing mitochondrial
metabolism. Interestingly, significantly greater proportions of
both WT and PGC-1α−/− IL-7R−KSL cells were undergoing
mitochondrial metabolism on day 4 post-5-FU than untreated
cells as indicated by NADH fluorescence pattern and an
increase in proportion of cells expressing NADH upon treat-
ment with antimycin A (Fig. S9Fi). Importantly, the amount of
NADH per cell was also high on day 4 post-5-FU treatment as
demonstrated by MFI of NADH fluorescence (Fig. S9Fi–ii).
However, NADH fluorescence intensity and pattern were
comparable between WT and PGC-1α−/− HSPCs on day 4
post-5-FU challenge when the mice were treated with
rapamycin (Fig. S9Fiv) unlike that observed in the absence of
rapamycin treatment (Fig. 3Diii). Concomitantly with changes
with lower mTORC1 activation and mitochondrial activity, the
proportion of both WT and PGC-1α−/− HSPCs undergoing
proliferation was also reduced (Fig. 6Bi–iv). In addition, this
regimen of rapamycin treatment did not have any significant
effect on the total number of early sub-populations of WT BM
cells on day 4 post-5-FU treatment, but it significantly
reduced total HSC and MP numbers and altered mature cell
composition in BM of PGC-1α−/− mice (Figs. S10A, B & D).
However, on day 7, the effect of rapamycin treatment on WT
hematopoietic recovery was pronounced—rapamycin led to
higher PBC count, BM cellularity, MPs and HSCs (Figs. S10Bi–iv
& C). The inhibitory effect of rapamycin on PGC-1α−/− HSPC
numbers is consistent with the finding that in PGC-1α−/−mice,
higher mTORC1 activation along with higher mitochondrial
capacity during early recovery phase that supports enhanced
proliferative potential is the major contributing factor for
increased HSPC pool in PGC-1α−/−mice. Rapamycin treatment
initiated early following 5-FU challenge resulted in recovery of
comparable numbers of MPs, MPPs and HSCs on day 6 in WT
and PGC-1α−/− mice (Fig. 6Ci–ii) and also led to comparable
competitive reconstituting ability ofWT and PGC-1α−/− BM cells
(Fig. 6Ciii), unlike the differences in repopulating activity ofWT
and PGC-1α−/− BM cells treated with 5-FU alone. Rapamycin
treatment also led to early recovery of blood cells in WT mice
(Fig. S10Cii) although it subdued the overshoot of blood cell
production that occurs during late recovery phase (Fig. 6Di).
Treatment of mice with a single dose of rapamycin on day
8 post-5-FU injection significantly reduced MPs, total BM
cellularity and PBC counts (Fig. 6Di–iii). Moreover, reduction
in MPs (particularly GMP and MEP) was higher when rapamycin
was administered on day 8 compared to early rapamycin
administration (on days 1 and 3) (Fig. 6Ciii). However, the
pronounced effect of rapamycin on WT HSC numbers when
administered during the early recovery phase was not
reproduced with rapamycin administration on day 8
(Fig. 6Cii). HSCs rapidly proliferate during days 2–5
post-5-FU challenge, and, thereafter, their proliferation
slows down (Lerner and Harrison, 1990; Hodgson and
Bradley, 1979). The current data show that the HSCs have
limited ability to boost mitochondrial biogenesis during
early phase, and, thus, suppression of mTORC1 activation by
rapamycin treatment during this phase would alleviate the
energy stress and thus preserve the HSCs. Thus, the
differential effect of rapamycin on WT HSC numbers basedon its administration schedule post-5-FU treatment is
consistent with these findings.
PGC-1α is also expressed by adipocytes in addition to
HSPCs( Puigserver and Spiegelman, 2003). Since adipocytes
are a type of stromal cell and influence hematopoiesis
(Greenberger, 1978), I next investigated whether the
differences between WT and PGC-1α−/− HSCs observed
during early hematopoietic recovery phase were hemato-
poietic cell intrinsic. To address this issue, recovery of
hematopoiesis following 5-FU challenge was analyzed in
chimeric mice. The chimeric mice were generated by
reconstituting hematopoiesis in lethally irradiated BoyJ
mice with BM cells from 5-FU treated WT or PGC-1α−/−
mice. Although HSC numbers after 5-FU treatment are
different in WT and PGC-1α−/−, rapamycin treatment on
days 1 and 3 post-5-FU challenge leads to comparable
numbers of HSCs in BM of WT and PGC-1α−/− mice following
5-FU treatment. Therefore, to inject comparable numbers
of HSCs, lethally irradiated BoyJ mice (CD45.1) were
transplanted with 2 × 105 BM cells from 6d 5-FU treated
WT or PGC-1α−/− mice that received rapamycin treatment
on days 1 and 3 post-5-FU challenge. At 7 months post-
transplantation, the chimeric mice had comparable levels of
donor derived blood cell in circulation (N97%) irrespective of
whether they received WT (WT/Boy/J chimeric) BM cells or
PGC-1α−/− (PGC-1α−/−/Boy/J chimeric) BM cells. Moreover,
both the BM and blood cellularity were also comparable
(Fig. S9Ai). Similarly, the contribution of donor derived MPs
and HSC enriched fractions (IL-7R−KSL) of cells in the BM of
chimeric mice were comparable (Fig. S11Aii–iii). However,
upon 5-FU treatment, BM cellularity, donor derived HSCs,
and MPs on day 5 were higher in PGC-1α−/−/BoyJ chimericmice
than WT/BoyJ chimeric mice (Fig. S11Bi–iii). Furthermore, on
day 5, similar to PGC-1α−/− mice, PGC-1α−/−/BoyJ chimeric
mice also had higher proportion of cells that were in cell cycle
compared to WT/BoyJ mice (Fig. S11C). Moreover, expression
of PRC, Tfam genes was higher and REDD-1 gene lower in
CD45.2 Lin− BM cells isolated from PGC-1α−/−/BoyJ chimeric
mice compared to corresponding cells isolated from WT/BoyJ
chimeric mice (Fig. S10D). These findings, thus, establish that
the differences in HSCs between WT and PGC-1α−/− mice
during early recovery phase following 5-FU challenge are
indeed hematopoietic cell intrinsic.Discussion
HSCs are relatively quiescent and proliferate slowly at
steady-state; obliteration of hematopoietic progenitors by
5-FU forces a majority of HSCs to undergo proliferation to
rescue hematopoiesis. Therefore, understanding recovery of
hematopoiesis following 5-FU treatment is an ideal model to
gain insight into the molecular mechanisms that regulate
HSC expansion in vivo. Growth factors responsible for driving
HSPC proliferation are elevated soon after 5-FU treatment
(Rich, 1991), however, the recovery of hematopoiesis
following 5-FU treatment appears to occur in two phases.
First, HSCs undergo rapid proliferation, and this is followed
by the second phase during which progenitor cells undergo
proliferation, leading to replenishment of mature hemato-
poietic cells in the BM and recovery of PBC count. The
current findings demonstrate that expression of PGC-1
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hematopoietic recovery. At steady-state, WT HSPCs express
all three known PGC-1 family members, but, during early
phase of hematopoietic recovery, only PRC is expressed in
HSPCs. During the later phase, expression of all the three
members of PGC-1 family reappears in HSPCs. Furthermore,
PRC plays an important role during the initial recovery
phase, while PGC-1α plays critical role in the later recovery
phase. mTORC1 activation, which drives HSPCs' prolifera-
tion, creates increased demand for energy in HSPCs, and the
current findings show that both mTORC1 activation level
and recovery of hematopoiesis following 5-FU are modulat-
ed by the mitochondrial activity of HSPCs.
During steady-state hematopoiesis, although HSCs are
mostly quiescent and undergo chiefly glycolytic metabolism
(Simsek et al., 2010; Takubo et al., 2010), they express all
known members of the PGC-1 family (Basu et al., 2013).
However, mitochondrial metabolism is limited in HSCs
during steady-state, probably due to restricted availability
of O2 in endosteal niche and high HIF-1α expression in these
cells (Simsek et al., 2010; Takubo et al., 2010). Also, severely
restricting dependence on mitochondrial metabolism derived
energy is critical for maintenance of HSCs at steady-state as
activation of mitochondrial metabolism due to loss of
autophagy gene Atg7 causes depletion of HSCs (Mortensen et
al., 2011). Interestingly, on day 4 post-5-FU challenge, both
PGC-1α/β expressions were undetectable in HSPCs. 5-FU
treatment leads to collapse of sinusoids in the bone marrow
and the killing of hematopoietic progenitor cells (Heissig et
al., 2002). Thus, availability of ‘oxygen pockets’ in the BM
post-5-FU treatment is likely to be lower than in unper-
turbed BM. In addition to mitochondrial ETC capacity,
availability of sufficient O2 is required during OXPHOS to
minimize the generation of superoxide and thus oxidative
stress. As 5-FU treatment leads to diminution of relatively
O2-rich regions in the BM, following very high mitochondrial
activity under these conditions would increase oxidative
stress in and cause loss of HSCs, which may explain why
expression of mitochondrial biogenesis genes is transiently
low in HSPCs post-5-FU treatment. The mechanism of regula-
tion of PGC-1 co-activators' expression in HSCs following 5-FU
related and other stress hematopoiesis is a subject for further
future study.
The second phase of hematopoietic recovery coincides
with the reappearance of expression of all members of
PGC-1 coactivators in WT HSPCs, enabling WT MPs to
increase mitochondrial biogenesis and metabolism. Inter-
estingly, although expression of all members of PGC-1
co-activators in WT progenitors was elevated during the
late recovery phase, expression in HSCs was comparable to
that of basal level. The late phase of recovery is characterized
by slowing HSC proliferation (Harrison and Lerner, 1991;
Randall and Weissman, 1997) and rapid increase in progen-
itor cell proliferation, leading to generation of sufficient
numbers of blood cells. Unlike in WT mice, expansion of MPs
during late recovery phase is impaired in PGC-1α−/− mice
(Fig. 3Bi). Proliferation of PGC-1α−/− HSCs also slows during
the second phase of recovery. However, the compounded
loss of PGC-1α and lower expression of PRC likely impair
cells' ability to generate sufficient mitochondrial depen-
dent energy leading to lower HSC number (Hao et al.,
2010).HSCs are sensitive to ROS; excessive ROS level following
mTOR activation has been reported to be the underlying
cause of HSC loss (Chen et al., 2008), although not always
(Lee et al., 2010). Since OXPHOS is a major source of cellular
ROS, it is likely that activation of mTOR in HSCs is modulated
to prevent significant buildup of ROS in HSCs. In support of
this argument, I found that the expression of REDD1, a
crucial inhibitor of mTOR activation (Brugarolas et al., 2004;
Reiling and Hafen, 2004), in HSCs correlated with mitochon-
drial ETC of HSCs. Interestingly, the findings of the current
study show that relatively higher apoptosis in WT HSCs was
not due to the higher level of ROS in these cells, as NAC
treatment initiated soon after 5-FU challenge did not
improve HSC numbers in WT mice (data not shown). Rather,
higher apoptosis of WT HSPCs during early recovery phase
was due to lower mitochondrial ETC capacity, and increased
mTOR activation. Although HSCs at steady-state mainly
undergo glycolytic metabolism (Simsek et al., 2010; Takubo
et al., 2010), findings of the current study demonstrate that
expansion of HSCs following 5-FU treatment is dependent
on mitochondrial metabolism. The critical role of mito-
chondria in HSCs' maintenance is further supported by the
findings that deficiency of Lkb1 leads to HSC depletion
(Nakada et al., 2010; Gurumurthy et al., 2010). Depletion
of HSCs in Lkb1 deficient mice is associated with
mitochondrial dysfunction and energy production (Gan
et al., 2010). Furthermore, I found lowering mTOR
activation during early phase by rapamycin treatment
preserved WT HSCs and led to their improved numbers
during later stage, likely by reducing energy stress.
Energy stress can lead to p53 activation resulting in
senescence (Lee et al., 2010) or apoptosis or reduction in
the ability to undergo symmetric division—critical for
stem cell expansion, as seen in mammary stem cells
(Cicalese et al., 2009).
The findings of this study show that mTORC1 activation can
lead to increased HSC proliferation provided the HSCs have the
capacity to boost ETC to meet the increased demand for
energy created by mTORC1 activation. An earlier study had
shown that mTOR activation leads to the loss of HSCs due to
increased mitochondrial metabolism (Chen et al., 2008).
Although the current findings appear to contradict the finding
of the previous study (Chen et al., 2008), differences in
hematopoiesis models—stress versus steady-state—analyzed
may account for the difference. Unlike steady-state, a
majority of HSCs undergo proliferation (Harrison and Lerner,
1991) post-5-FU treatment to replenish hematopoiesis. 5-FU
treatment leads to myeloablation and loss of a majority of
sinusoidal microvasculature in BM (Kopp et al., 2005). It is
likely that the loss of BM microvasculature severely restricts
the availability of nutrients. Although ATP can be derived from
glycolysis, OXPHOS yields maximum ATP molecules per
molecule of glucose. It is therefore likely that post-5-FU
treatment HSCs boost mitochondrial metabolism to meet the
increased energy demand required to support rapid prolifer-
ation of HSCs. Indeed the difference in proportion of IL-7R-KSL
cells undergoing mitochondrial metabolism post-5-FU treat-
ment compared to that of untreated cells (as shown by NADH
fluorescence pattern in the presence and absence of
antimycin A) supports the conjecture and demonstrates an
increase in mitochondrial metabolism in HSCs during initial
recovery of hematopoietic phase following 5-FU treatment,
192 S. Basuunlike steady-state hematopoiesis, during which glycolysis is
required for the maintenance of HSCs (Simsek et al., 2010).
However, if the HSCs lack the ability to enhance ETC activity in
tune with increased mTORC1 activity, mTORC1 activation
leads to the loss of HSCs, as observed in the case of WT mice.
Thus, a fine tuning between mTORC1 activation and mito-
chondrial biogenesis is important for efficient expansion of
HSPCs following 5-FU treatment.
In future studies, agents that enhance expression of PGC
family members will be identified and exploited for improving
in vitro expansion of HSPCs.
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.scr.2013.10.006.Acknowledgments
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